C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC) Healthcare & Pipeline Overview

C4 Therapeutics, Inc. pioneers targeted protein degradation therapeutics, developing orally bioavailable MonoDAC and BiDAC degraders for cancer and neurodegenerative diseases. The company's clinical-stage pipeline and strategic collaborations position it within the competitive biotechnology landscape, addressing unmet needs in oncology and beyond.

What Is the Investment Thesis for CCCC?

C4 Therapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative approach to targeted protein degradation. The company's lead candidate, CFT7455, is currently in Phase 1/2 trials, and positive clinical data could serve as a significant catalyst for stock appreciation. Furthermore, the development of CFT8634, CFT1946, and CFT8919, along with earlier-stage programs, diversifies the pipeline and mitigates risk. Strategic collaborations with Roche, Biogen, and Calico provide validation of C4 Therapeutics' technology and potential for future revenue streams. However, the company's high beta of 2.86 indicates significant volatility, and a negative profit margin of -292.1% highlights the need for continued funding and successful clinical outcomes. The company's market capitalization is $0.25B as of 2026-05-09.

Based on FMP financials and quantitative analysis

CCCC Key Highlights

• Lead product candidate CFT7455 is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas.
• Developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors.
• Developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies.
• Developing CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
• Strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC.

Who Are CCCC's Competitors?

CCCC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CCCC's Key Strengths?

• Innovative targeted protein degradation technology.
• Strong pipeline of clinical and preclinical therapeutic candidates.
• Strategic collaborations with leading pharmaceutical companies.
• Experienced management team with expertise in drug development.

What Are CCCC's Weaknesses?

• Clinical-stage company with no approved products.
• High research and development costs.
• Dependence on strategic collaborations for funding.
• Negative profit margin.

What Could Drive CCCC Stock Higher?

• Clinical trial data releases for CFT7455 in multiple myeloma and non-Hodgkin lymphomas.
• Initiation of clinical trials for CFT8634 in synovial sarcoma and SMARCB1-deleted solid tumors.
• Advancement of CFT1946 and CFT8919 into clinical development.
• Expansion of strategic collaborations with pharmaceutical and biotechnology companies.
• Progress in earlier-stage programs targeting RET degraders for various cancers.

What Are the Key Risks for CCCC?

• Financial-distress signal — its Altman Z-Score of -1.13 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-48.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for lead product candidates.
• Competition from other companies developing targeted protein degradation therapies.
• Regulatory delays or rejection of marketing applications.
• High cash burn rate and dependence on external funding.
• Intellectual property disputes and patent challenges.

What Are the Growth Opportunities for CCCC?

• Expansion of CFT7455 Clinical Trials: C4 Therapeutics has the opportunity to expand the clinical trials for CFT7455 to include additional indications and patient populations. Success in these trials could lead to accelerated regulatory approval and market access, potentially capturing a significant share of the multiple myeloma and non-Hodgkin lymphoma treatment markets, which are projected to reach billions of dollars by 2030. The timeline for this growth opportunity is dependent on clinical trial progress and regulatory review.
• Advancement of BRD9 Degrader (CFT8634): The development of CFT8634, targeting BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, presents a significant growth opportunity. These tumor types often lack effective treatments, creating a high unmet medical need. Positive preclinical and clinical data for CFT8634 could lead to orphan drug designation and accelerated development pathways, potentially resulting in a first-in-class therapy with substantial market potential within the next 3-5 years.
• Development of BRAF Degrader (CFT1946): CFT1946, targeting V600X mutant BRAF, offers a growth opportunity in melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer. These cancers are prevalent and often develop resistance to existing therapies. Successful development of CFT1946 could provide a novel treatment option and capture a portion of these large oncology markets, with potential for clinical trial initiation within the next 2 years.
• EGFR L858R Degrader (CFT8919) for NSCLC: The development of CFT8919, an EGFR L858R degrader for NSCLC, represents a targeted approach to a specific mutation driving cancer growth. This precision medicine strategy has the potential to deliver improved outcomes for patients with this mutation. The NSCLC market is substantial, and a successful EGFR L858R degrader could capture a significant share, with potential for clinical trial initiation within the next 2-3 years.
• Expansion of Strategic Collaborations: C4 Therapeutics can leverage its expertise in targeted protein degradation to expand its strategic collaborations with pharmaceutical and biotechnology companies. These collaborations can provide access to new targets, funding, and development resources, accelerating the advancement of its pipeline and expanding its market reach. The company's existing partnerships with Roche, Biogen, and Calico demonstrate the potential for future collaborations to drive growth.

What Opportunities Does CCCC Have?

• Expansion of clinical trials to new indications.
• Advancement of pipeline candidates to late-stage development.
• Securing regulatory approval for lead product candidate CFT7455.
• Expanding strategic collaborations and licensing agreements.

What Threats Does CCCC Face?

• Clinical trial failures.
• Competition from other biotechnology and pharmaceutical companies.
• Regulatory hurdles and delays.
• Patent challenges and intellectual property disputes.

What Are CCCC's Competitive Advantages?

• Proprietary MonoDAC and BiDAC degrader technology.
• Strong intellectual property portfolio protecting its therapeutic candidates.
• Strategic collaborations with leading pharmaceutical and biotechnology companies.
• Expertise in targeted protein degradation and drug development.

What Does CCCC Do?

C4 Therapeutics, Inc., founded in 2015 and headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of cancer, neurodegenerative conditions, and other diseases through targeted protein degradation. The company's innovative approach centers on developing novel therapeutic candidates designed to selectively degrade disease-causing proteins. Its lead product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein currently undergoing Phase 1/2 clinical trials. This trial targets IKZF1 and IKZF3 for the treatment of multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Beyond CFT7455, C4 Therapeutics is advancing a pipeline of additional protein degraders, including CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target relevant to synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, another orally bioavailable BiDAC degrader, targets V600X mutant BRAF for the treatment of melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader, targets epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. The company also has earlier stage programs focused on RET degraders for various cancers. C4 Therapeutics has established strategic collaborations with industry leaders such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC, enhancing its research and development capabilities and expanding the potential reach of its therapeutic candidates. These collaborations underscore the company's commitment to advancing the field of targeted protein degradation and delivering innovative treatments to patients in need.

What Products and Services Does CCCC Offer?

• Develops novel therapeutic candidates to degrade disease-causing proteins.
• Focuses on treatments for cancer, neurodegenerative conditions, and other diseases.
• Creates orally bioavailable MonoDAC and BiDAC degraders.
• Conducts Phase 1/2 clinical trials for lead product candidate CFT7455.
• Targets IKZF1 and IKZF3 proteins for multiple myeloma and non-Hodgkin lymphomas.
• Develops BRD9 degraders for synovial sarcoma and SMARCB1-deleted solid tumors.
• Develops V600X mutant BRAF degraders for melanoma, NSCLC, and colorectal cancer.
• Develops EGFR L858R degraders for NSCLC.

How Does CCCC Make Money?

• Develops and patents novel protein degradation technologies.
• Conducts preclinical and clinical research to validate therapeutic candidates.
• Out-licenses or co-develops therapeutic candidates with pharmaceutical partners.
• Generates revenue through licensing agreements, milestone payments, and royalties.

What Industry Does CCCC Operate In?

C4 Therapeutics operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high research and development costs, and stringent regulatory requirements. The company's focus on targeted protein degradation positions it within a niche segment of the oncology and neurodegenerative disease markets. The broader biotechnology industry is experiencing growth driven by technological advancements, increasing prevalence of chronic diseases, and rising demand for personalized medicine. C4 Therapeutics competes with other companies developing novel therapies for cancer and neurodegenerative disorders, requiring continuous innovation and strategic partnerships to maintain a competitive edge.

Who Are CCCC's Key Customers?

• Pharmaceutical companies seeking novel therapeutic candidates.
• Biotechnology companies looking to expand their pipelines.
• Patients with cancer, neurodegenerative conditions, and other diseases.
• Healthcare providers prescribing novel therapies.

FY2026 estForward Outlook

Wall Street analysts project C4 Therapeutics, Inc. revenue of about $23.2M for fiscal 2026, with EPS near $-0.93. The estimate reflects 3 contributing analysts.

F-Score 3/9Financial Health

C4 Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.13 places it in the distress zone, a signal of elevated financial risk.

ROE -48%Key Financial Metrics

Return on equity for C4 Therapeutics, Inc. stands at -48.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -19.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

C4 Therapeutics, Inc. (CCCC) Valuation Context

Valued at $356.16M, CCCC is classified as a small-cap stock. Relative to its peer group, CCCC's quantitative score of 13/100 is below the peer average of 86/100.

CCCC Revenue & Earnings Trend

In Q1 2026, CCCC generated $6.2M in top-line revenue, marking a sequential decrease of 44.2%. The company recorded a net loss of $25.1M, with diluted EPS of $-0.20. Revenue has contracted over three consecutive quarters, which investors in this small-cap Healthcare stock should monitor closely. Across the four most recent quarters, CCCC averaged $-0.30 in diluted EPS.

Company Profile

C4 Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, US. The company is led by CEO Andrew J. Hirsch. CCCC has traded publicly since 2020.

CCCC Financials

CCCC Latest News

CCCC Analyst Consensus

CCCC MoonshotScore

Common Questions About CCCC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources